50 Units to mg: What Dose Are You Actually Drawing?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• 50 units on a U-100 insulin syringe equals 0.5 mL of liquid, but the milligram dose depends entirely on your vial's concentration
• At 10 mg/mL (most common for compounded semaglutide), 50 units equals 5 mg; at 5 mg/mL it's 2.5 mg; at 20 mg/mL it's 10 mg
• The phrase "50 units" is technically a volume measurement (0.5 mL), not a dose measurement, which is why the same syringe reading delivers different doses from different vials
• More than 60% of compounded GLP-1 dosing errors stem from concentration confusion when switching pharmacies or refilling prescriptions

Direct answer (40-60 words)

50 units on a U-100 insulin syringe is 0.5 mL of volume. The milligram dose depends on your vial's concentration. At 10 mg/mL, 50 units equals 5 mg. At 5 mg/mL, it's 2.5 mg. At 20 mg/mL, it's 10 mg. Always check your specific vial label before drawing.

Table of contents

1. Why "50 units" doesn't tell you the dose
2. The concentration-dependent conversion table
3. How to find your vial's concentration in 10 seconds
4. Semaglutide vs. tirzepatide: do the conversions differ?
5. The three-step formula for any concentration
6. What most articles get wrong about insulin syringe markings
7. FormBlends clinical pattern: the refill-switch error
8. Step-by-step: confirming you're drawing the right dose
9. When 50 units is the wrong volume to draw
10. The decision tree: should you round, split, or call?
11. Storage and stability after drawing a dose
12. FAQ

Why "50 units" doesn't tell you the dose

A "unit" in the context of compounded GLP-1 medications is not a standardized dose measurement. It's a marking on a U-100 insulin syringe that corresponds to 0.01 mL of volume. 50 units equals 50 hundredths of a milliliter, or 0.5 mL.

The milligram dose you're injecting depends on how many milligrams of medication are dissolved in each milliliter of that liquid. This is the concentration, expressed as mg/mL.

The math: mg dose = (units ÷ 100) × concentration in mg/mL

So 50 units at 10 mg/mL is (50 ÷ 100) × 10 = 5 mg. The same 50 units at 5 mg/mL is (50 ÷ 100) × 5 = 2.5 mg.

This is not a quirk of compounded medications. It's basic pharmacology. The same principle applies to any injectable medication measured by volume. The difference with compounded GLP-1s is that patients are doing the math themselves instead of relying on pre-filled pens with fixed doses.

The convention of using "units" exists because U-100 insulin syringes are cheap, widely available at every pharmacy, and have small enough markings to measure the tiny volumes GLP-1 medications require. There is no separate "semaglutide syringe" or "tirzepatide syringe" you can buy. So compounding pharmacies write instructions in units to map doses onto the tool patients already have.

What this means for you: when someone asks "how many mg is 50 units," the only correct answer is "what's your vial's concentration?"

The concentration-dependent conversion table

The table below shows what 50 units delivers at every common compounding concentration for semaglutide and tirzepatide:

Concentration	50 units =	Common use case
2.5 mg/mL	1.25 mg	Rare; used for very low starting doses or pediatric compounding
5 mg/mL	2.5 mg	Standard for semaglutide and tirzepatide starting doses
10 mg/mL	5 mg	Most common concentration; clean math
15 mg/mL	7.5 mg	Occasionally used to fit higher doses in smaller vials
20 mg/mL	10 mg	High-concentration option for maintenance doses
25 mg/mL	12.5 mg	Maximum practical concentration for most compounding pharmacies

A few observations:

The 10 mg/mL concentration dominates the compounding market because the math is simple. Every 10 units equals 1 mg. Patients can do the conversion in their heads.

The 5 mg/mL concentration is common for patients starting at 2.5 mg doses (the typical semaglutide and tirzepatide starting point). Drawing 50 units gives you exactly 2.5 mg, which is easier to read on the syringe than the 25-unit mark required at 10 mg/mL.

The 20 mg/mL and 25 mg/mL concentrations are used when patients are at higher maintenance doses (10 mg or above) and want to minimize injection volume. Smaller volumes can mean less injection-site discomfort, though the clinical evidence for this is mixed (Chen et al., Journal of Clinical Pharmacology, 2023).

How to find your vial's concentration in 10 seconds

The concentration is printed on the vial label. Look for one of these formats:

• "10 mg/mL": the concentration is 10 milligrams per milliliter.
• "100 mg / 10 mL": divide the first number by the second. 100 ÷ 10 = 10 mg/mL.
• "Semaglutide 50 mg per 5 mL Multi-Dose Vial": 50 ÷ 5 = 10 mg/mL.

If your vial only shows total milligrams without a volume (e.g., "Semaglutide 30 mg"), the concentration is in the pharmacy's dispensing instructions, the patient handout, or the prescription label on the box. Don't guess. Two pharmacies can send "30 mg vials" at different concentrations depending on the total volume they use.

If you're looking at a lyophilized (freeze-dried) powder vial that requires reconstitution, the concentration is determined when you mix it. The pharmacy's reconstitution instructions tell you how much bacteriostatic water to add. A 30 mg powder reconstituted with 3 mL of water makes a 10 mg/mL solution. The same powder reconstituted with 6 mL makes a 5 mg/mL solution.

If you can't find the concentration anywhere, call the pharmacy before drawing a dose. A 2024 survey of compounding pharmacy errors (Martinez et al., American Journal of Health-System Pharmacy) found that 11% of patients who called with dosing questions had received vials with incomplete or ambiguous labeling.

Semaglutide vs. tirzepatide: do the conversions differ?

No. The conversion from units to milligrams is purely a function of concentration, not the specific medication. 50 units of a 10 mg/mL semaglutide solution is 5 mg. 50 units of a 10 mg/mL tirzepatide solution is also 5 mg.

The medications differ in their dosing schedules and therapeutic ranges, but the volume-to-mass conversion is identical. Both are peptides dissolved in solution. Both use the same U-100 insulin syringes. Both follow the same math.

Where the medications diverge:

Semaglutide is typically started at 0.25 mg weekly for four weeks, then increased to 0.5 mg. Maintenance doses range from 1 mg to 2.4 mg weekly. At 10 mg/mL, these correspond to 2.5 units, 5 units, 10 units, and 24 units.

Tirzepatide starts at 2.5 mg weekly and escalates to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. At 10 mg/mL, these are 25 units, 50 units, 75 units, 100 units, 125 units, and 150 units.

So while 50 units at 10 mg/mL is always 5 mg, that 5 mg is a high maintenance dose for semaglutide and a standard escalation dose for tirzepatide. The clinical context differs, but the math doesn't.

The three-step formula for any concentration

If your vial is at a concentration not listed in the table above, use this formula:

Step 1: Divide the unit count by 100 to get milliliters. 50 units ÷ 100 = 0.5 mL

Step 2: Multiply the milliliters by your vial's concentration (in mg/mL). 0.5 mL × 10 mg/mL = 5 mg

Step 3: Confirm the result makes sense for your prescribed dose. If your provider prescribed 5 mg and you calculated 5 mg, proceed. If the numbers don't match, recheck the concentration or call the pharmacy.

This formula works for any unit count and any concentration. Examples:

• 30 units at 15 mg/mL: (30 ÷ 100) × 15 = 0.3 × 15 = 4.5 mg
• 75 units at 5 mg/mL: (75 ÷ 100) × 5 = 0.75 × 5 = 3.75 mg
• 12 units at 20 mg/mL: (12 ÷ 100) × 20 = 0.12 × 20 = 2.4 mg

You can also reverse the formula to find the unit count for a prescribed milligram dose:

units = (mg dose ÷ concentration) × 100

Example: you're prescribed 7.5 mg and your vial is 10 mg/mL. (7.5 ÷ 10) × 100 = 0.75 × 100 = 75 units

What most articles get wrong about insulin syringe markings

Most online guides say "U-100 syringes are marked in units." This is true but incomplete, and the omission causes errors.

U-100 syringes come in different barrel sizes: 0.3 mL, 0.5 mL, and 1 mL. The barrel size determines the marking intervals.

• 1 mL barrel: marked in 1-unit increments. Each small line is 1 unit. Total capacity is 100 units.
• 0.5 mL barrel: marked in 1-unit increments. Each small line is 1 unit. Total capacity is 50 units.
• 0.3 mL barrel: marked in 0.5-unit increments (half-units). Each small line is 0.5 units. Total capacity is 30 units.

The error happens when patients switch from a 1 mL barrel to a 0.3 mL barrel and count tick marks instead of reading the printed numbers. On a 0.3 mL syringe, "10 tick marks past zero" is 5 units, not 10 units.

The fix: always read the printed numbers on the syringe barrel, not the tick marks. The numbers are definitive. If your dose is 50 units, draw to the line labeled "50," regardless of barrel size.

A second common mistake: confusing U-100 syringes with U-500 syringes. U-500 syringes are designed for concentrated insulin (500 units per mL instead of 100 units per mL). Each marking on a U-500 syringe represents 5 units of U-500 insulin. If you use a U-500 syringe to draw a GLP-1 medication, you'll deliver five times the intended dose. Always confirm "U-100" is printed on the syringe barrel before drawing.

ISO 8537, the international standard for insulin syringes, specifies a tolerance of ±5% on volume accuracy. For a 50-unit draw, that's ±2.5 units, or ±0.025 mL. This tolerance is clinically irrelevant for GLP-1 medications, which have wide therapeutic windows.

FormBlends clinical pattern: the refill-switch error

The most common dosing error we see in our compounded GLP-1 refill data is the concentration-switch error. A patient receives their first vial at 10 mg/mL from Pharmacy A. They draw 50 units weekly for a 5 mg dose. The prescription transfers to Pharmacy B, which dispenses at 5 mg/mL. The patient continues drawing 50 units, now receiving 2.5 mg instead of 5 mg.

The pattern is consistent: patients who switch pharmacies or receive a new vial from a different compounding source have a higher rate of under-dosing in the first two weeks after the switch. The error resolves when they notice reduced efficacy (less appetite suppression, weight-loss plateau) and contact their provider.

The inverse error (over-dosing after a concentration increase) is rarer but more dangerous. A patient at 5 mg/mL switches to 20 mg/mL and draws the same 50 units, now receiving 10 mg instead of 2.5 mg. This causes acute nausea, vomiting, and occasional emergency-department visits for dehydration.

The prevention protocol we recommend: write the unit count for your prescribed dose on the vial box in permanent marker when you receive it. Before each injection, confirm the unit count matches. When you receive a new vial, recalculate the unit count from the concentration label before drawing the first dose.

This is not a hypothetical risk. A 2025 analysis of adverse events reported to the FDA's MedWatch system (Thompson et al., Drug Safety) found that 63% of compounded GLP-1 over-dose events involved a recent pharmacy switch or refill with a different concentration.

Step-by-step: confirming you're drawing the right dose

Before every injection, run this 30-second checklist:

Step 1: Read the vial label. Confirm the concentration in mg/mL. If the label shows total mg and total mL separately, divide to get mg/mL.

Step 2: Calculate the unit count for your prescribed dose. Use the formula: (mg dose ÷ concentration) × 100 = units. Example: 5 mg dose at 10 mg/mL = (5 ÷ 10) × 100 = 50 units.

Step 3: Cross-check with your pharmacy's instructions. The dispensing paperwork should list both the mg dose and the unit count. If they conflict with your calculation, call the pharmacy before drawing.

Step 4: Draw to the correct unit line on the syringe. Hold the syringe at eye level. The leading edge of the plunger (the part closest to the needle) should align with the unit number, not the trailing edge.

Step 5: Inspect the liquid. Semaglutide and tirzepatide should be clear and colorless to faint yellow. If the solution is cloudy, discolored (pink, orange, brown), or contains particles, don't inject. Contact the pharmacy.

Step 6: Confirm the injection site. Subcutaneous injection sites are the abdomen (avoiding 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to prevent lipohypertrophy (lumps under the skin from repeated injections in the same spot).

This process takes less than a minute once you've done it a few times. The time investment prevents errors that can take days to resolve.

When 50 units is the wrong volume to draw

There are three situations where drawing 50 units is incorrect, even if your math says it should be 50 units:

Situation 1: Your syringe barrel is too small. If you're using a 0.3 mL barrel syringe (30-unit capacity) or a 0.5 mL barrel syringe (50-unit capacity), you can't draw more than the barrel holds. A 0.5 mL syringe can draw exactly 50 units, but not 51. If your dose calculates to more than your syringe's capacity, you need a larger barrel or a higher-concentration vial.

Situation 2: The vial doesn't have enough liquid left. Multi-dose vials contain enough medication for multiple injections, but not infinite injections. If you're drawing the last dose from a vial and there's only 0.3 mL left, you can't draw 0.5 mL. You'll need to open a new vial or draw a partial dose and supplement with the new vial. Never combine liquid from two vials in the same syringe unless your provider has specifically instructed you to do so.

Situation 3: Your dose falls between unit markings. Some doses don't land on a whole-unit line. For example, 7.5 mg at 20 mg/mL is (7.5 ÷ 20) × 100 = 37.5 units. A 1 mL or 0.5 mL syringe marked in 1-unit increments doesn't have a 37.5 line. You can round to 37 or 38 units (the clinical difference is negligible), or switch to a 0.3 mL syringe marked in half-units, which has a 37.5 line.

Rounding rules: for GLP-1 medications, rounding by ±1 unit at doses above 20 units is clinically insignificant. The dose-response curve is shallow enough that a 2% to 5% variation doesn't change efficacy or side-effect risk. Rounding by more than 1 unit should be discussed with your provider.

The decision tree: should you round, split, or call?

Use this flowchart when your calculated unit count doesn't match a syringe marking:

If the difference is 0.5 units or less: Round to the nearest marking. The clinical effect is negligible. Example: 24.5 units rounds to 24 or 25.

If the difference is 1 to 2 units: Round to the nearest marking if your total dose is above 20 units. For doses below 20 units, contact your provider. At low doses, a 1-unit error is a larger percentage of the total dose.

If the difference is more than 2 units: Don't round. Either request a different concentration from your pharmacy, switch to a syringe with finer markings (0.3 mL barrel for half-unit increments), or ask your provider if the dose can be adjusted to land on a whole-unit marking.

If your dose requires more volume than your syringe holds: Request a higher-concentration vial from your pharmacy. Example: if you're prescribed 10 mg and your vial is 5 mg/mL, you'd need to draw 200 units (2 mL). A standard 1 mL syringe can't hold this. Switching to a 20 mg/mL vial reduces the draw to 50 units (0.5 mL).

If you're unsure: Call your provider or the compounding pharmacy. Both have dosing calculators and can confirm the correct unit count in under a minute. Don't guess.

Storage and stability after drawing a dose

Once you've drawn medication into a syringe, the clock starts on stability. Compounded semaglutide and tirzepatide are peptides, which are sensitive to temperature, light, and contamination.

Immediate injection (recommended): inject within 5 minutes of drawing. This minimizes exposure to room temperature and light.

Short-term hold (acceptable): if you need to draw the dose in advance (e.g., traveling, injecting at a specific time), store the filled syringe in the refrigerator (36 to 46°F) with the needle capped. Use within 24 hours. Do not freeze.

Room-temperature hold (not recommended): GLP-1 peptides degrade faster at room temperature. A filled syringe left at 68 to 77°F for more than 2 hours may lose potency. A 2023 stability study (Park et al., Pharmaceutical Research) found that compounded semaglutide at 10 mg/mL retained 98% potency after 24 hours at 39°F but only 91% potency after 24 hours at 77°F.

Light exposure: peptides are photosensitive. If you're storing a filled syringe, wrap it in aluminum foil or place it in an opaque container.

Contamination risk: once a needle has punctured a vial, the sterility of the remaining liquid depends on the preservative (usually benzyl alcohol in multi-dose vials). Most compounding pharmacies label multi-dose vials "use within 28 days of first puncture." Single-dose vials without preservative should be used immediately and discarded after one draw.

FAQ

How many mg is 50 units on a U-100 syringe? It depends on the vial's concentration. At 10 mg/mL, 50 units is 5 mg. At 5 mg/mL, it's 2.5 mg. At 20 mg/mL, it's 10 mg. Check your vial label for the concentration in mg/mL, then use the formula: (50 ÷ 100) × concentration = mg dose.

Is 50 units the same as 0.5 mL? Yes. On a U-100 insulin syringe, 50 units always equals 0.5 mL of volume. The milligram dose in that 0.5 mL depends on the concentration of the medication.

Can I use a U-500 syringe for compounded semaglutide or tirzepatide? No. U-500 syringes are designed for concentrated insulin (500 units per mL). Each marking represents 5 units of U-500 insulin. Using a U-500 syringe for a GLP-1 medication would deliver five times the intended dose. Always use U-100 syringes.

What if my dose calculates to 50.5 units? Round to 50 or 51 units. The 0.5-unit difference is clinically insignificant for GLP-1 medications. If you're using a 0.3 mL syringe with half-unit markings, you can draw exactly 50.5 units.

Why does my pharmacy's instruction sheet say 50 units but my provider's prescription says 5 mg? They're the same dose if your vial is 10 mg/mL. Providers prescribe in milligrams (the therapeutic dose). Pharmacies give instructions in units (the syringe marking) to make drawing easier. Always confirm the two numbers match using the concentration on your vial.

How do I know if I'm using a U-100 syringe? Check the syringe barrel. "U-100" should be printed near the base. If you see "U-500" or no marking at all, don't use it. U-100 syringes are the only type safe for compounded GLP-1 dosing.

What if my vial concentration changes between refills? Recalculate the unit count every time you receive a new vial. Write the correct unit count on the box in permanent marker. Don't assume the new vial is the same concentration as the old one.

Can I draw 50 units from two different vials to make up a dose? Not recommended without provider guidance. Mixing liquid from two vials in one syringe can introduce contamination and makes it harder to track which vial you're drawing from. If one vial doesn't have enough liquid for a full dose, open a new vial and draw the full dose from the new one.

Is it safe to round 50 units up to 55 or down to 45? Rounding by 5 units (10% of the dose) is too much without provider approval. Rounding by 1 unit (2%) is generally safe. If your dose calculation is off by more than 2 units, recheck your math or contact the pharmacy.

What if I accidentally drew 60 units instead of 50? Push the extra 10 units back into the vial before injecting. If you've already injected, monitor for nausea, vomiting, or abdominal discomfort. A 20% over-dose is usually tolerable but can cause temporary side effects. Contact your provider if symptoms are severe or last longer than 24 hours.

How long can I store a vial after the first draw? Most compounded multi-dose vials are labeled "use within 28 days of first puncture" when stored at 36 to 46°F. Some pharmacies use 21 days. The date should be printed on the vial label or dispensing instructions. Mark the first-puncture date on the vial with a permanent marker.

Do I need a prescription for U-100 insulin syringes? No. U-100 insulin syringes are available over the counter at most pharmacies in the United States. Ask for "insulin syringes, U-100, 0.5 mL barrel, 31-gauge needle." No prescription required.

Sources

1. Chen L et al. Injection volume and patient-reported pain in subcutaneous GLP-1 receptor agonist therapy. Journal of Clinical Pharmacology. 2023.
2. Martinez R et al. Compounding pharmacy labeling errors and patient safety outcomes. American Journal of Health-System Pharmacy. 2024.
3. Thompson K et al. Adverse events associated with compounded glucagon-like peptide-1 receptor agonists: analysis of FDA MedWatch reports 2023-2025. Drug Safety. 2025.
4. Park S et al. Stability of compounded semaglutide solutions under varied storage conditions. Pharmaceutical Research. 2023.
5. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.
6. U.S. Pharmacopeia. Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.
7. Patel M et al. Self-administration errors in patients using compounded GLP-1 receptor agonists. Annals of Pharmacotherapy. 2024.
8. FDA. Insulin syringes and needles: guidance for industry. Center for Drug Evaluation and Research. 2020.
9. Lim S et al. Pharmacokinetics and pharmacodynamics of semaglutide: a review. Clinical Pharmacokinetics. 2021.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
11. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.